Free Trial
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Gemini Therapeutics logo
$47.37 -0.67 (-1.39%)
As of 05/23/2025

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Key Stats

Today's Range
$46.80
$47.56
50-Day Range
$34.28
$53.74
52-Week Range
$1.16
$14.10
Volume
132,011 shs
Average Volume
189,291 shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GMTX Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

GMTX Stock Analysis - Frequently Asked Questions

Gemini Therapeutics' stock was trading at $63.40 at the beginning of 2025. Since then, GMTX stock has decreased by 25.3% and is now trading at $47.37.
View the best growth stocks for 2025 here
.

Gemini Therapeutics, Inc. (NASDAQ:GMTX) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04.

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Video Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

Last Earnings
11/15/2021
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMTX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-71,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
16.39

Miscellaneous

Free Float
37,739,000
Market Cap
$2.05 billion
Optionable
Not Optionable
Beta
-0.12
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:GMTX) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners